Figure 1.

The identification of dabrafenib that promotes Schwann cell differentiation in vitro. (A) Chemical structure of dabrafenib. (B) Primary rat Schwann cells were treated with either DMSO (0.1%) or dabrafenib (10 µM) for 48 h and subjected to indirect immunofluorescence with an anti-Oct6 antibody. Wide-field fluorescence images from four fields in each well of a 384-well plate were acquired, and the fluorescence intensity of Oct6 expression divided by the number of cells is shown. Each column represents the mean ± SD, n = 3. *** p < 0.001, DMSO versus dabrafenib. (C) Primary rat Schwann cells were treated with either DMSO (0.1%), dabrafenib (10 µM), or dibutyryl cAMP (500 µM) for 24 or 48 h, and the total lysates were subject to western blot analyses. Band intensities were quantitated using ImageJ and normalized to actin intensities. Fold changes are indicated at the top of each lane. (D) The primary Schwann cells were treated with either DMSO (0.1%), dibutyryl cAMP (500 µM), or increasing concentrations of dabrafenib for 48 h, and the total lysates were subject to western blot analyses. (E) Primary rat Schwann cells were treated with either DMSO or the indicated chemicals for 48 h, and the total lysates were subject to Western blot analyses.